Real‐world treatment patterns and outcomes using terlipressin in 203 patients with the hepatorenal syndrome

BACKGROUND: Hepatorenal syndrome and acute kidney injury are common complications of decompensated cirrhosis, and terlipressin is recommended as first‐line vasoconstrictor therapy. However, data on its use outside of clinical trials are lacking. AIMS: To assess practice patterns and outcomes around...

Descripción completa

Detalles Bibliográficos
Autores principales: Moore, Kevin, Jamil, Khurram, Verleger, Katharina, Luo, Linlin, Kebede, Nehemiah, Heisen, Marieke, Corman, Shelby, Leonardi, Roberta, Bakker, Rachel, Maï, Christine, Shamseddine, Nisreen, Huang, Xingyue, Allegretti, Andrew S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Terlipressin in Hepatorenal Syndrome
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7383732/
https://www.ncbi.nlm.nih.gov/pubmed/32495956
http://dx.doi.org/10.1111/apt.15836

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7383732/
https://www.ncbi.nlm.nih.gov/pubmed/32495956
http://dx.doi.org/10.1111/apt.15836

Ejemplares similares